Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
McKesson ( (MCK) ) just unveiled an announcement.
McKesson Corporation announced that starting in the second quarter of fiscal 2026, it will report financial results across four new segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This restructuring reflects the company’s strategic focus on innovation and efficiency, and aims to provide clearer insights into its operations for stakeholders. Additionally, McKesson plans to sell its Norwegian operations, with the transaction expected to close following regulatory approvals.
The most recent analyst rating on (MCK) stock is a Buy with a $800.00 price target. To see the full list of analyst forecasts on McKesson stock, see the MCK Stock Forecast page.
Spark’s Take on MCK Stock
According to Spark, TipRanks’ AI Analyst, MCK is a Neutral.
McKesson’s overall stock score is driven by strong earnings call results and solid financial performance, particularly in revenue growth and cash flow generation. However, the high leverage and modest valuation metrics present risks. The technical analysis suggests a neutral market position, with no strong momentum in either direction.
To see Spark’s full report on MCK stock, click here.
More about McKesson
McKesson Corporation operates in the healthcare industry, providing pharmaceutical distribution, oncology and multispecialty solutions, prescription technology solutions, and medical-surgical supply distribution. The company focuses on delivering innovative solutions to meet the evolving needs of healthcare providers, patients, and the industry.
Average Trading Volume: 762,792
Technical Sentiment Signal: Buy
Current Market Cap: $86.1B
For an in-depth examination of MCK stock, go to TipRanks’ Overview page.